Danielle van Westen1, Filip Szczepankiewicz2, Karin Bryskhe3, Pia Sundgren1,4, and Markus Nilsson1
1Diagnostic Radiology, Lund University, Lund, Sweden, 2Medical Radiation Physics, Lund University, Lund, Sweden, 3CR Development, Lund, Sweden, 4Center for Imaging and function, Skane University hospital, Sweden
Synopsis
In this work we present a novel approach based on tensor-valued diffusion encoding to quantify tumor tissue characteristics such as cell shape and cell density variation
—
features considered in histopathology. This approach constitutes a promising framework for non-invasive diagnostic and prognostic assessment of tumors that may improve patient care by
non-invasively capturing histopathological
information on cell shape and cell density heterogenity.
Clinical Question
How can histopathological information on
cell shape and cell density heterogeneity in intracranial tumors be obtained preoperatively
and non-invasively?Impact
Cancer will be the leading cause of death in the next decade
according to WHO. Total cost for cancer care, premature death, and disability
is larger than for any other disease.1 In 2012, intracranial brain
tumors were the cause of death of 200,000 people worldwide. Additional 250,000 people were
diagnosed with intracranial brain tumors on that year.2 High-grade
primary brain tumors are amongst the deadliest, with median survival time of 12–14 months and a
10% 5-year survival. Surgery is a cornerstone in
the treatment of intracranial tumors. A complete resection and cure are attainable
in benign tumors such as meningiomas, and longtime survival is correlated with the
extent of resection in high-grade primary brain tumors.
MRI is the first step in the routine preoperative workup for
intracranial tumors, and is the main tool for visualization of tumor extent and
basic characterization of the tumor. However, at present, the level of characterization
obtained by MRI is not sufficient by itself for diagnosis and prognosis of
tumors. As such, currently, definitive diagnosis is obtained by surgical biopsy.
Biopsy is associated with risk for hemorrhage, infection, and seeding. Complications occur in 6–12% of cases.3 Surgical biopsy and resection must be directed
towards the most malignant tumor component, warranting comprehensive preoperative
characterization of the tumor tissue. It would be extremely beneficial if the
characterization could be performed by MRI. This would remove the risk
associated with invasive biopsies. Thus it is highly desirable for patient
management to extend the current routine MRI with new clinical sequences for the
determination of histopathological features.
Approach
Conventional dMRI is an excellent method for detecting changes of
tissue microstructure, but unfortunately it suffers from low specificity, since
it cannot distinguish between tumors characterized by different types of cellular
microstructural arrangements observed by histopathology. For example, the apparent diffusion
coefficient (ADC) obtained with conventional dMRI is an average metric that
cannot capture microstructural heterogeneity within individual voxels. Our innovation4 is a multidimensional
framework that relies on tensor-valued diffusion encoding to quantify tumor
heterogeneity such as cell shape and intra-voxel cell density variation also
obtained from histopathology (Fig 1).5 This framework is used for
the DIVIDE protocol, which in brain tumors provides parameters that show
excellent agreement with corresponding histopathology parameters (Fig 2).5 Cell shape and cell density heterogeneity
from histopathology were respectively described by the anisotropic
variance (MKA) and the isotropic heterogeneity (MKI). Importantly,
and unlike conventional dMRI methods, such as DTI, the MKA parameter
from DIVIDE can detect and estimate the diffusion anisotropy even in structures
that are disordered, which is frequently the case in tumors.
Gains and Losses
Our results show the abilities
of the innovation to provide non-invasive characterization of cell shape and
variation in cell density in tumors in good agreement with histopathology.5
In cases where the tumor grade and type are mainly characterized by cell shape
and variations in cell density, DIVIDE may improve the diagnostic procedure.
For example, meningioma and glioma tumors could be differentiated based on
their cell shape (Fig 3).5 We hypothesize that presurgical planning
could be improved in meningioma tumors by assessing their toughness from DIVIDE,
which cannot be done from conventional dMRI alone.6 Total scan time
is less than 8 min, which allows DIVIDE to supplement a standard clinical
protocol, to plan and guide the surgical biopsy and/or resection.
While DIVIDE provides
important characterizations of cell shape and cell density variations, it is
limited in its ability to characterize more subtle features such as irregular
nuclei shapes and sizes, frequency of mitosis etc. Additional studies are
needed to explore the correlation between DIVIDE parameters and different grades and
types of intracranial tumors, as well as to validate the sensitivity of DIVIDE
for the evaluation of treatment effect, although previous studies suggest that
a correlation should exist between tumor grade and diffusional variance7, 8.
DIVIDE is comparable to routine dMRI with regards to patient safety.
Preliminary data
Our
results, published by Szczepankiewicz et al.5, constitute initial evidence
of the link between DIVIDE parameters and histopathological measures (Fig 2), which
potentially enables non-invasive tumor characterization. The cost for surgical
biopsies (a single biopsy costs on average $15000 including hospitalization)2 could be significantly
reduced if a fraction of these were replaced with MRI methods such as DIVIDE,
which approximately costs $1000-5000. In addition, presurgical planning of the biopsy as well
as resection may be improved leading to reduced need of additional biopsies and
more efficient tumor resection.Acknowledgements
References
1. John
R et al. The Global Economic Cost of Cancer. American Cancer Society and the
LIVESTRONG organization (2010).
2. Cancer
research UK (http://www.cancerresearchuk.org/home-page).
3. Malone
et al. Complications Following
Stereotactic Needle Biopsy of Intracranial Tumors. World Neurosurg., (2015).
4. Lasic
et al. Microanisotropy imaging: quantification of microscopic diffusion
anisotropy and orientational order parameter by diffusion MRI with magic-angle
spinning of the q-vector. Front. Physics 2, (2014).
5. Szczepankiewicz
et al. The link between diffusion MRI and tumor heterogeneity: Mapping cell
eccentricity and density by diffusional variance decomposition (DIVIDE).
NeuroImage, (2016).
6. Tropine
et al. Differentiation of Fibroblastic
Meningiomas From Other Benign Subtypes Using Diffusion Tensor Imaging. J. Magn. Reson. Imaging, (2007)Beckers Hospital Review (http://www.beckershospitalreview.com).
7. Raab
et al. Cerebral gliomas: diffusional kurtosis imaging analysis of
microstructural differences, Radiology, (2010)
8. Van
Cauter et al. Gliomas: diffusion kurtosis MR imaging in grading. Radiology,
(2012)